李柏昕醫師
引用
![](/Content/img/icon-printer.png)
![現在日期](/Content/img/zixun/zixun_11.jpg)
![科別分類符號](/Content/img/icon-flag.png)
主治專長
肺癌、肺部結節、高壓氧治療、經皮氣切手術、睡眠呼吸障礙、肺阻塞、氣喘、一般胸腔疾病(咳嗽、肺結核、肺炎)、一般內科疾病、呼吸道相關疾病
專業經驗
臺中榮總胸腔內科主治醫師
肺癌整合照護暨研究中心主治醫師
高壓氧治療中心主治醫師
肺癌整合照護暨研究中心主治醫師
高壓氧治療中心主治醫師
重要經歷/進修訓練
臺中榮總胸腔內科主治醫師
臺中榮總胸腔內科總醫師
臺中榮總內科部住院醫師
臺中榮總胸腔內科總醫師
臺中榮總內科部住院醫師
學歷
國立成功大學醫學系
國立中興大學轉譯醫學博士學位學程進修中
國立中興大學轉譯醫學博士學位學程進修中
專科證照
內科專科
胸腔暨重症專科
高壓氧專科
重症專科
胸腔暨重症專科
高壓氧專科
重症專科
教師資格
教育部定講師
國立陽明交通大學講師
胸腔暨重症加護醫學會專科醫師指導醫師
國立陽明交通大學講師
胸腔暨重症加護醫學會專科醫師指導醫師
研究興趣
肺癌、高壓氧。
進行中之計劃
利用家族史以及基因檢測增加低劑量電腦斷層篩檢肺癌之準確度
雄性賀爾蒙與其抑制劑在肺癌之角色
雄性賀爾蒙與其抑制劑在肺癌之角色
代表作
(1)Lee, Po-Hsin, et al. Benefits of NGS in Advanced Lung Adenocarcinoma Vary by Populations and Timing of Examination. Int. J. Mol. Sci. 2024, 25(13), 6949
(2)Lee, Po-Hsin, et al. Comparing the Real-World Efficacy of Erlotinib and Afatinib in Treating Advanced Lung Squamous Cell Carcinoma. Thorac Med 2023; 38: 187-198
(3)Lee, Po-Hsin, et al. "Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma." Frontiers in Oncology 13 (2023).
stage Ib肺腺癌病患術後接受輔助性化學治療之優劣
(4)Lee, Po-Hsin, et al. Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. J. Clin. Med. 2023, 12, 231. https://doi.org/10.3390/jcm12010231
肺癌病患使用標靶藥物後產生B型肝炎活化之研究
(5)Chu, C. H., Huang, Y. H., Lee, P. H. et al (2022). Various impacts of driver mutations on the PD-L1 expression of NSCLC. Plos one, 17(8), e0273207.
肺癌病患不同基因突變其PD-L1表現與其預後之分析
(6)Lee, Po-Hsin, et al. "Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma." Medicina 58.7 (2022): 908.
肺癌病患接受第三代EGFR標靶治療後產生病理型態改變之分析
(7)Wu, J. J., Lee, P. H., et al. (2022). Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant). Medicine, 101(24), e29381-e29381.
KRAS陽性病患使用免疫檢查點抑制劑之探討
(8)Lee, Po-Hsin, et al. "Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients." Anti-Cancer Drugs 32.10 (2021): 1099-1104.
ALK陽性病患使用lorlatinib治療之分析
(9)Lee, Po-Hsin, et al. "Prognostic Factors to Predict ICU Mortality in Patients with Severe ARDS Who Received Early and Prolonged Prone Positioning Therapy." Journal of clinical medicine 10.11 (2021): 2323.
急性呼吸窘迫症候群之病患使用俯臥通氣預後之分析
(10)Lee, Po-Hsin, "Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report." Clinical lung cancer (2020): S1525-7304.
肺癌病患使用osimertinib之後產生病理型態變化之個案報告
(11)Lee, Po-Hsin, "Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection." European journal of cancer (Oxford, England: 1990) 130 (2020): 272-274.
肺癌病患使用osimertinib標靶藥物後產生B型肝炎再活化之報導
(12)李柏昕, et al. "急性呼吸窘迫症候群 (ARDS) 使用俯臥式通氣模式 (Prone positioning) 之預後影響因子探討." 內科學誌 30.2 (2019): 96-106.
(13)Lee, Po-Hsin, "Pulmonary Embolism and Severe Asthma: Case Report and Literature Review." Medicina 55.10 (2019): 647.
嚴重氣喘病患併發肺栓塞之報導以及文獻回顧
(14)Lee, Po-Hsin, et al. "Snakebite (Protobothrops mucrosquamatus)-related myositis." Journal of the Formosan Medical Association= Taiwan yi zhi 118.7 (2019): 1168.
以超音波診斷蛇咬造成之肌肉發炎個案報導
(15)Lee, Po‐Hsin, "A 27‐year‐old female presented with diffuse alveolar haemorrhage due to breast angiosarcoma with lung metastasis." Respirology Case Reports 7.5 (2019): e0419.
肺部血管肉瘤以肺部出血為表現之個案報導
(16)Lee, Po-Hsin "Coinfection of pneumocystis jiroveci pneumonia and pulmonary apergillosis in a non-HIV-infected patient." Journal of microbiology, immunology, and infection= Wei mian yu gan ran za zhi 51.6 (2018): 860.
肺部同時感染肺囊蟲及肺麴菌之個案報導
(17)Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
使用免疫檢查點抑制劑之肺癌病人治療後產生肋膜積液其CD4/CD8比例高者預後較佳
(2)Lee, Po-Hsin, et al. Comparing the Real-World Efficacy of Erlotinib and Afatinib in Treating Advanced Lung Squamous Cell Carcinoma. Thorac Med 2023; 38: 187-198
(3)Lee, Po-Hsin, et al. "Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma." Frontiers in Oncology 13 (2023).
stage Ib肺腺癌病患術後接受輔助性化學治療之優劣
(4)Lee, Po-Hsin, et al. Reactivation of Hepatitis B Virus in Lung Cancer Patients Receiving Tyrosine Kinase Inhibitor Treatment. J. Clin. Med. 2023, 12, 231. https://doi.org/10.3390/jcm12010231
肺癌病患使用標靶藥物後產生B型肝炎活化之研究
(5)Chu, C. H., Huang, Y. H., Lee, P. H. et al (2022). Various impacts of driver mutations on the PD-L1 expression of NSCLC. Plos one, 17(8), e0273207.
肺癌病患不同基因突變其PD-L1表現與其預後之分析
(6)Lee, Po-Hsin, et al. "Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced EGFR-Mutant Lung Adenocarcinoma." Medicina 58.7 (2022): 908.
肺癌病患接受第三代EGFR標靶治療後產生病理型態改變之分析
(7)Wu, J. J., Lee, P. H., et al. (2022). Characteristics and immune checkpoint inhibitor effects on non-smoking non-small cell lung cancer with KRAS mutation: A single center cohort (STROBE-compliant). Medicine, 101(24), e29381-e29381.
KRAS陽性病患使用免疫檢查點抑制劑之探討
(8)Lee, Po-Hsin, et al. "Real-world efficacy and safety of lorlatinib in treating advanced ALK-positive non–small cell lung cancer patients." Anti-Cancer Drugs 32.10 (2021): 1099-1104.
ALK陽性病患使用lorlatinib治療之分析
(9)Lee, Po-Hsin, et al. "Prognostic Factors to Predict ICU Mortality in Patients with Severe ARDS Who Received Early and Prolonged Prone Positioning Therapy." Journal of clinical medicine 10.11 (2021): 2323.
急性呼吸窘迫症候群之病患使用俯臥通氣預後之分析
(10)Lee, Po-Hsin, "Transformations First Into Squamous-Cell Carcinoma and Later Into Sarcomatoid Carcinoma After Acquired Resistance to Osimertinib in a Patient With EGFR-Mutant Lung Adenocarcinoma: Case Report." Clinical lung cancer (2020): S1525-7304.
肺癌病患使用osimertinib之後產生病理型態變化之個案報告
(11)Lee, Po-Hsin, "Hepatitis B flare during osimertinib targeted therapy in a lung cancer patient with a resolved hepatitis B virus infection." European journal of cancer (Oxford, England: 1990) 130 (2020): 272-274.
肺癌病患使用osimertinib標靶藥物後產生B型肝炎再活化之報導
(12)李柏昕, et al. "急性呼吸窘迫症候群 (ARDS) 使用俯臥式通氣模式 (Prone positioning) 之預後影響因子探討." 內科學誌 30.2 (2019): 96-106.
(13)Lee, Po-Hsin, "Pulmonary Embolism and Severe Asthma: Case Report and Literature Review." Medicina 55.10 (2019): 647.
嚴重氣喘病患併發肺栓塞之報導以及文獻回顧
(14)Lee, Po-Hsin, et al. "Snakebite (Protobothrops mucrosquamatus)-related myositis." Journal of the Formosan Medical Association= Taiwan yi zhi 118.7 (2019): 1168.
以超音波診斷蛇咬造成之肌肉發炎個案報導
(15)Lee, Po‐Hsin, "A 27‐year‐old female presented with diffuse alveolar haemorrhage due to breast angiosarcoma with lung metastasis." Respirology Case Reports 7.5 (2019): e0419.
肺部血管肉瘤以肺部出血為表現之個案報導
(16)Lee, Po-Hsin "Coinfection of pneumocystis jiroveci pneumonia and pulmonary apergillosis in a non-HIV-infected patient." Journal of microbiology, immunology, and infection= Wei mian yu gan ran za zhi 51.6 (2018): 860.
肺部同時感染肺囊蟲及肺麴菌之個案報導
(17)Higher CD4/CD8 ratio of pleural effusion predicts better survival for lung cancer patients receiving immune checkpoint inhibitors
使用免疫檢查點抑制劑之肺癌病人治療後產生肋膜積液其CD4/CD8比例高者預後較佳
其他
(2023) 臺中榮總院級臨床教學績優醫師
(2023) 第一屆煦陽溫和大地優良醫學論文獎 青年醫師-住院醫師組 第一名
(2022) 臺中榮總青年醫師優良論文第二名
(2020) EBM實證醫學第二名
(2020) 胸重醫學會Junior Research Award優秀論文獎
(2020) 內科部研究進度報告第二名
(2020) 臺中榮總院級臨床教學績優住院醫師
(2019) 內科學誌優秀論文獎綜論類第一名
(2023) 第一屆煦陽溫和大地優良醫學論文獎 青年醫師-住院醫師組 第一名
(2022) 臺中榮總青年醫師優良論文第二名
(2020) EBM實證醫學第二名
(2020) 胸重醫學會Junior Research Award優秀論文獎
(2020) 內科部研究進度報告第二名
(2020) 臺中榮總院級臨床教學績優住院醫師
(2019) 內科學誌優秀論文獎綜論類第一名